The benefit of the hemonetics ® cell saver apparatus during cardiac surgery
This retrospective chart review of 155 patients having coronary artery bypass graft surgery (CABG) over a two-month period determined whether the use of a cell saver apparatus (CSA) (1) reduced or increased the requirements for homologous blood; (2) increased the incidence of post-surgical bleeding;...
Gespeichert in:
| Veröffentlicht in: | Canadian journal of anesthesia 1990-09, Vol.37 (6), p.618-623 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 623 |
|---|---|
| container_issue | 6 |
| container_start_page | 618 |
| container_title | Canadian journal of anesthesia |
| container_volume | 37 |
| creator | HALL, R. I SCHWEIGER, I. M FINLAYSON, D. C |
| description | This retrospective chart review of 155 patients having coronary artery bypass graft surgery (CABG) over a two-month period determined whether the use of a cell saver apparatus (CSA) (1) reduced or increased the requirements for homologous blood; (2) increased the incidence of post-surgical bleeding; (3) was cost-effective. Two groups of patients were identified. Group 1 (n = 99) received both CSA processed red blood cells and homologous blood components. Requirement for homologous blood products was reduced in the first 24 hr after surgery (0.5 +/- 1.0 vs 1.3 +/- 1.8 units; P less than 0.05) when compared with Group 2 (n = 56) in whom only homologous blood products were utilized. More patients in Group 1 had no transfusion requirements (45 vs 8; P less than 0.05) and there was no increased risk of major haemorrhage. When the capital costs are included, utilization of the CSA was not cost-effective. We conclude that utilisation of a CSA was safe, with no increased risk of bleeding, reduced requirements for homologous blood transfusions, but added to the cost of the procedure. |
| doi_str_mv | 10.1007/bf03006478 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80017685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80017685</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-130509d25d7261eeb30aecbd0115e300ac022f5423b5d992088e0bc0d7298a583</originalsourceid><addsrcrecordid>eNpFkE1LxDAQhoMo67p68S7kogehOkmaNjnq4qqw4GUFbyVNp7uVfpm0wv4pf4S_zC5b9TQM78PLzEPIOYMbBhDfpjkIgCiM1QGZslBHgdKxPCRTUIIHEYO3Y3Li_TsAqEiqCZlwxrQGmJLlaoM0xRrzoqNNTrth3WDV1NgV1tPvL2qxLKk3n-ioaVvjTNd7mvWuqNfUGpcVxlLfuzW67Sk5yk3p8WycM_K6eFjNn4Lly-Pz_G4Z2JCFXcAESNAZl1nMI4aYCjBo0wwYkzg8YixwnsuQi1RmWnNQCiG1MOBaGanEjFzte1vXfPTou6Qq_O5OU2PT-0QBsDhScgCv96B1jfcO86R1RWXcNmGQ7NQl94tfdQN8Mbb2aYXZHzq6GvLLMTfemjJ3praF_2_UPBaac_EDicV1RQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80017685</pqid></control><display><type>article</type><title>The benefit of the hemonetics ® cell saver apparatus during cardiac surgery</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>HALL, R. I ; SCHWEIGER, I. M ; FINLAYSON, D. C</creator><creatorcontrib>HALL, R. I ; SCHWEIGER, I. M ; FINLAYSON, D. C</creatorcontrib><description>This retrospective chart review of 155 patients having coronary artery bypass graft surgery (CABG) over a two-month period determined whether the use of a cell saver apparatus (CSA) (1) reduced or increased the requirements for homologous blood; (2) increased the incidence of post-surgical bleeding; (3) was cost-effective. Two groups of patients were identified. Group 1 (n = 99) received both CSA processed red blood cells and homologous blood components. Requirement for homologous blood products was reduced in the first 24 hr after surgery (0.5 +/- 1.0 vs 1.3 +/- 1.8 units; P less than 0.05) when compared with Group 2 (n = 56) in whom only homologous blood products were utilized. More patients in Group 1 had no transfusion requirements (45 vs 8; P less than 0.05) and there was no increased risk of major haemorrhage. When the capital costs are included, utilization of the CSA was not cost-effective. We conclude that utilisation of a CSA was safe, with no increased risk of bleeding, reduced requirements for homologous blood transfusions, but added to the cost of the procedure.</description><identifier>ISSN: 0832-610X</identifier><identifier>EISSN: 1496-8975</identifier><identifier>DOI: 10.1007/bf03006478</identifier><identifier>PMID: 2119900</identifier><identifier>CODEN: CJOAEP</identifier><language>eng</language><publisher>Toronto, ON: Canadian Anesthesiologists' Society</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood Transfusion ; Blood Transfusion, Autologous - adverse effects ; Blood Transfusion, Autologous - economics ; Blood Transfusion, Autologous - instrumentation ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Cardiopulmonary Bypass ; Coronary Artery Bypass ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Equipment Design ; Female ; Hematocrit ; Hemorrhage - etiology ; Humans ; Intraoperative Care ; Length of Stay ; Male ; Medical sciences ; Middle Aged ; Postoperative Complications ; Retrospective Studies ; Risk Factors ; Time Factors ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Canadian journal of anesthesia, 1990-09, Vol.37 (6), p.618-623</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-130509d25d7261eeb30aecbd0115e300ac022f5423b5d992088e0bc0d7298a583</citedby><cites>FETCH-LOGICAL-c414t-130509d25d7261eeb30aecbd0115e300ac022f5423b5d992088e0bc0d7298a583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19273922$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2119900$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HALL, R. I</creatorcontrib><creatorcontrib>SCHWEIGER, I. M</creatorcontrib><creatorcontrib>FINLAYSON, D. C</creatorcontrib><title>The benefit of the hemonetics ® cell saver apparatus during cardiac surgery</title><title>Canadian journal of anesthesia</title><addtitle>Can J Anaesth</addtitle><description>This retrospective chart review of 155 patients having coronary artery bypass graft surgery (CABG) over a two-month period determined whether the use of a cell saver apparatus (CSA) (1) reduced or increased the requirements for homologous blood; (2) increased the incidence of post-surgical bleeding; (3) was cost-effective. Two groups of patients were identified. Group 1 (n = 99) received both CSA processed red blood cells and homologous blood components. Requirement for homologous blood products was reduced in the first 24 hr after surgery (0.5 +/- 1.0 vs 1.3 +/- 1.8 units; P less than 0.05) when compared with Group 2 (n = 56) in whom only homologous blood products were utilized. More patients in Group 1 had no transfusion requirements (45 vs 8; P less than 0.05) and there was no increased risk of major haemorrhage. When the capital costs are included, utilization of the CSA was not cost-effective. We conclude that utilisation of a CSA was safe, with no increased risk of bleeding, reduced requirements for homologous blood transfusions, but added to the cost of the procedure.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Transfusion</subject><subject>Blood Transfusion, Autologous - adverse effects</subject><subject>Blood Transfusion, Autologous - economics</subject><subject>Blood Transfusion, Autologous - instrumentation</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Cardiopulmonary Bypass</subject><subject>Coronary Artery Bypass</subject><subject>Cost-Benefit Analysis</subject><subject>Costs and Cost Analysis</subject><subject>Equipment Design</subject><subject>Female</subject><subject>Hematocrit</subject><subject>Hemorrhage - etiology</subject><subject>Humans</subject><subject>Intraoperative Care</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Postoperative Complications</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0832-610X</issn><issn>1496-8975</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LxDAQhoMo67p68S7kogehOkmaNjnq4qqw4GUFbyVNp7uVfpm0wv4pf4S_zC5b9TQM78PLzEPIOYMbBhDfpjkIgCiM1QGZslBHgdKxPCRTUIIHEYO3Y3Li_TsAqEiqCZlwxrQGmJLlaoM0xRrzoqNNTrth3WDV1NgV1tPvL2qxLKk3n-ioaVvjTNd7mvWuqNfUGpcVxlLfuzW67Sk5yk3p8WycM_K6eFjNn4Lly-Pz_G4Z2JCFXcAESNAZl1nMI4aYCjBo0wwYkzg8YixwnsuQi1RmWnNQCiG1MOBaGanEjFzte1vXfPTou6Qq_O5OU2PT-0QBsDhScgCv96B1jfcO86R1RWXcNmGQ7NQl94tfdQN8Mbb2aYXZHzq6GvLLMTfemjJ3praF_2_UPBaac_EDicV1RQ</recordid><startdate>19900901</startdate><enddate>19900901</enddate><creator>HALL, R. I</creator><creator>SCHWEIGER, I. M</creator><creator>FINLAYSON, D. C</creator><general>Canadian Anesthesiologists' Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900901</creationdate><title>The benefit of the hemonetics ® cell saver apparatus during cardiac surgery</title><author>HALL, R. I ; SCHWEIGER, I. M ; FINLAYSON, D. C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-130509d25d7261eeb30aecbd0115e300ac022f5423b5d992088e0bc0d7298a583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Transfusion</topic><topic>Blood Transfusion, Autologous - adverse effects</topic><topic>Blood Transfusion, Autologous - economics</topic><topic>Blood Transfusion, Autologous - instrumentation</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Cardiopulmonary Bypass</topic><topic>Coronary Artery Bypass</topic><topic>Cost-Benefit Analysis</topic><topic>Costs and Cost Analysis</topic><topic>Equipment Design</topic><topic>Female</topic><topic>Hematocrit</topic><topic>Hemorrhage - etiology</topic><topic>Humans</topic><topic>Intraoperative Care</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Postoperative Complications</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HALL, R. I</creatorcontrib><creatorcontrib>SCHWEIGER, I. M</creatorcontrib><creatorcontrib>FINLAYSON, D. C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HALL, R. I</au><au>SCHWEIGER, I. M</au><au>FINLAYSON, D. C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The benefit of the hemonetics ® cell saver apparatus during cardiac surgery</atitle><jtitle>Canadian journal of anesthesia</jtitle><addtitle>Can J Anaesth</addtitle><date>1990-09-01</date><risdate>1990</risdate><volume>37</volume><issue>6</issue><spage>618</spage><epage>623</epage><pages>618-623</pages><issn>0832-610X</issn><eissn>1496-8975</eissn><coden>CJOAEP</coden><abstract>This retrospective chart review of 155 patients having coronary artery bypass graft surgery (CABG) over a two-month period determined whether the use of a cell saver apparatus (CSA) (1) reduced or increased the requirements for homologous blood; (2) increased the incidence of post-surgical bleeding; (3) was cost-effective. Two groups of patients were identified. Group 1 (n = 99) received both CSA processed red blood cells and homologous blood components. Requirement for homologous blood products was reduced in the first 24 hr after surgery (0.5 +/- 1.0 vs 1.3 +/- 1.8 units; P less than 0.05) when compared with Group 2 (n = 56) in whom only homologous blood products were utilized. More patients in Group 1 had no transfusion requirements (45 vs 8; P less than 0.05) and there was no increased risk of major haemorrhage. When the capital costs are included, utilization of the CSA was not cost-effective. We conclude that utilisation of a CSA was safe, with no increased risk of bleeding, reduced requirements for homologous blood transfusions, but added to the cost of the procedure.</abstract><cop>Toronto, ON</cop><pub>Canadian Anesthesiologists' Society</pub><pmid>2119900</pmid><doi>10.1007/bf03006478</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0832-610X |
| ispartof | Canadian journal of anesthesia, 1990-09, Vol.37 (6), p.618-623 |
| issn | 0832-610X 1496-8975 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80017685 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood Transfusion Blood Transfusion, Autologous - adverse effects Blood Transfusion, Autologous - economics Blood Transfusion, Autologous - instrumentation Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Cardiopulmonary Bypass Coronary Artery Bypass Cost-Benefit Analysis Costs and Cost Analysis Equipment Design Female Hematocrit Hemorrhage - etiology Humans Intraoperative Care Length of Stay Male Medical sciences Middle Aged Postoperative Complications Retrospective Studies Risk Factors Time Factors Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | The benefit of the hemonetics ® cell saver apparatus during cardiac surgery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T16%3A50%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20benefit%20of%20the%20hemonetics%20%C2%AE%20cell%20saver%20apparatus%20during%20cardiac%20surgery&rft.jtitle=Canadian%20journal%20of%20anesthesia&rft.au=HALL,%20R.%20I&rft.date=1990-09-01&rft.volume=37&rft.issue=6&rft.spage=618&rft.epage=623&rft.pages=618-623&rft.issn=0832-610X&rft.eissn=1496-8975&rft.coden=CJOAEP&rft_id=info:doi/10.1007/bf03006478&rft_dat=%3Cproquest_cross%3E80017685%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80017685&rft_id=info:pmid/2119900&rfr_iscdi=true |